Background: Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that maintains the typical features of C cells. An advanced stage and the presence of lymph node metastases at diagnosis have been demonstrated to be the most important bad prognostic factors. Somatic RET mutations have been found in 40-50% of MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial and have been performed in small series with short-term follow ups. The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up.

Methods: We studied 100 sporadic MTC patients with a 10.2 yr mean follow-up. RET gene exons 10-11 and 13-16 were analyzed. The correlation between the presence/absence of a somatic RET mutation, clinical/pathological features, and outcome of MTC patients was evaluated.

Results: A somatic RET mutation was found in 43 of 100 (43%) sporadic MTCs. The most frequent mutation (34 of 43, 79%) was M918T. RET mutation occurrence was more frequent in larger tumors (P=0.03), and in MTC with node and distant metastases (P<0.0001 and P=0.02, respectively), thus, a significant correlation was found with a more advanced stage at diagnosis (P=0.004). A worse outcome was also significantly correlated with the presence of a somatic RET mutation (P=0.002). Among all prognostic factors found to be correlated with a worse outcome, at multivariate analysis only the advanced stage at diagnosis and the presence of a RET mutation showed an independent correlation (P<0.0001 and P=0.01, respectively). Finally, the survival curves of MTC patients showed a significantly lower percentage of surviving patients in the group with RET mutations (P=0.006).

Conclusions: We demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow up. More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2007-1714DOI Listing

Publication Analysis

Top Keywords

somatic ret
20
ret mutation
12
medullary thyroid
8
ret mutations
8
mtc patients
8
ret
7
somatic
6
prognostic significance
4
significance somatic
4
ret oncogene
4

Similar Publications

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that originate from chromaffin cells and occur in the adrenal medulla and in the sympathetic or parasympathetic ganglia. Nearly 70% of PPGLs result from germline or somatic mutations in a single driver gene. The aim of this study was to characterize the genetic background and clinical characteristics related to genetic profile of patients with PPGLs from Romania.

View Article and Find Full Text PDF

Mechanisms of resistance to RET-directed therapies.

Endocr Relat Cancer

December 2024

R Clifton-Bligh, Endocrinology, Royal North Shore Hospital, Sydney, 2065, Australia.

The association between RET and multiple endocrine neoplasia type 2 was established in 1993 and remains one of the very few oncogenes for which distinct phenotypes (medullary thyroid cancer or phaeochromocytoma) are associated with the same hot-spot variants occurring either in germline or somatic DNA. Somatic RET fusion events have also been described in several cancers, including papillary thyroid cancer, non-small cell lung cancer, breast cancer, salivary gland cancer and pancreatic cancer. Highly selective RET inhibitors have improved outcomes in RET-altered cancers and have been well tolerated.

View Article and Find Full Text PDF

[Application of 9-gene panel in assisting fine needle aspiration cytology to diagnose thyroid cancer].

Zhonghua Zhong Liu Za Zhi

November 2024

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, China.

Article Synopsis
  • The study investigates the effectiveness of a 9-gene panel for diagnosing thyroid nodules that have indeterminate cytological results, compared to traditional BRAF V600E single-gene detection.
  • Researchers analyzed 579 thyroid nodule samples from patients, using next-generation sequencing to identify mutations in nine specific genes associated with cancer.
  • The results showed that 47.5% of tested nodules had mutations, with a majority of identified malignant cases linked to the BRAF gene, demonstrating the panel's potential as a diagnostic tool alongside standard cytology methods.
View Article and Find Full Text PDF
Article Synopsis
  • - Medullary thyroid carcinoma (MTC) is a rare cancer linked to mutations in the RET proto-oncogene, with specific treatments available for cases involving these mutations.
  • - Selective RET inhibitors have been approved for clinical use, showing effectiveness with low toxicity, but treatment options are limited for patients with RET-negative MTC.
  • - Peptide receptor radionuclide therapy (PRRT) is being explored as a potential option for treatment, although its effectiveness compared to current therapies is still being studied.
View Article and Find Full Text PDF
Article Synopsis
  • Thyroid cancer management is evolving with the use of actionable biomarkers from genetic testing, which helps guide treatment decisions for patients.
  • An expert panel developed consensus algorithms and recommendations for testing specific types of thyroid cancer to improve patient care and address existing disparities in biomarker testing.
  • The recommendations aim to assist physicians in effectively navigating the complexities of thyroid cancer biomarker testing while considering financial and practical constraints, ensuring a multidisciplinary approach for optimal treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!